Raffaele Colombo: Tisotumab vedotin as 2nd or 3rd line therapy for recurrent cervical cancer
Raffaele Colombo shared a post on X about recent paper by Ignace Vergote et al. published in The New England Journal of Medicine, commenting:
“Tisotumab vedotin as 2nd or 3rd line therapy for recurrent cervical cancer (innovaTV 301).
Out on New England Journal of Medicine.
As always, interesting appendix data!
Of note, correlation or lack of between tissue factor expression as TF H-Score and responses for this Antibody-drug-conjugates (ADC).”
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Authors: AntonioGonzález-Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, Jung-Yun Lee, Susana Banerjee, Fernando Cotait Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen, Luis Manso, Linn Woelber, Anneke Westermann, Allan Covens, Kosei Hasegawa, Byoung-Gie Kim, MiriamRaimondo, Maria Bjurberg, Felipe Melo Cruz, Antoine Angelergues, David Cibula, Lisa Barraclough, Ana Oaknin, Christine Gennigens, Leo Nicacio, Melinda Siew LengTeng, Elizabeth Whalley, IbrahimaSoumaoro, and Brian M. Slomovitz.
Additional information
Source: Raffaele Colombo/X
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
